Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: Results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 895-900

  Van Dartel, Sanne A A ^a   Fransen, Jaap ^a   Kievit, Wietske ^a   Flendrie, Marcel ^a,b   Den Broeder, Alfons A ^b   Visser, H ^c   Hartkamp, A ^d   Van De Laar, Mart A F J ^e   Van Riel, Piet L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sint Maartenskliniek ^*  (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ABDOMINAL INFECTION; ADULT; AGE; ARTICLE; ATTRIBUTABLE RISK; CARDIOVASCULAR INFECTION; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; DRUG RESPONSE; EAR NOSE THROAT DISEASE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SENSITIVITY ANALYSIS; SEPTICEMIA; SKIN INFECTION; SOFT TISSUE INFECTION; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFECTION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; RISK; SEVERITY OF ILLNESS INDEX;

EID: 84877598742     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201338     Document Type: Article

References (30)

1. Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:345-63.
2. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
3. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33. (Pubitemid 46608637)
4. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76. (Pubitemid 44204996)
5. Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009;8:266-73.
6. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124-31.
7. Katikireddi VS, Whittle SL, Hill CL. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. Int J Rheum Dis 2010;13:12-26.
8. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12. (Pubitemid 41612206)
9. Bernatsky S, Habel Y, Rahme E. Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. J Rheumatol 2010;37:928-31.
10. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
11. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39:327-46.
12. Keystone EC. Does anti-tumor necrosis factor-{alpha} therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol 2011;38:1552-62.
13. Curtis JR, Xie F, Chen L, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011;70:1401-6.
14. Dixon WG, Symmons DP, Lunt M, et al . Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904. (Pubitemid 47502735)
15. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.
16. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
17. Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010;30:339-53.
18. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;CD008794-
19. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005;34:34-8.
20. Mpofu S, Fatima F, Moots RJ. Anti-TNF-alpha therapies: they are all the same (aren't they?). Rheumatology (Oxford) 2005;44:271-3. (Pubitemid 40361279)
21. Kievit W, Fransen J, Adang EM, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011;50:196-203.
22. Code of Federal Regulations (CFR). http://www.fda.gov/default.htm
23. Greene C, Lowe G, Taggart C, et al. Tumor necrosis factor-alpha- converting enzyme: its role in community-acquired pneumonia. J Infect Dis 2002;186:1790-6. (Pubitemid 35463512)
24. Grijalva CG, Kaltenbach L, Arbogast PG, et al. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) 2010;49:82-90.
25. Lane MA, McDonald JR, Zeringue AL, et al. TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine 2011;90:139-45.
26. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331-9.
27. Sakai R, Komano Y, Tanaka M, et al. Time-dependent increased risk for serious infection from continuous use of TNF antagonists during three years in rheumatoid arthritis patients. Arthritis Care Res 2012;64:1125-34.
28. Toh S, Li L, Harrold LR, et al. Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics? Pharmacoepidemiol Drug Saf 2012;21:524-34.
29. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
30. Donders AR, van der Heijden GJ, Stijnen T, et al. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006;59:1087-91. (Pubitemid 44374314)